Overview

Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma

Status:
Unknown status

Trial end date:
2021-04-01

Target enrollment:

Participant gender:

Summary

- To evaluate the efficacy of bendamustine in combination with rituximab as first line in patients with follicular lymphoma, 1-3A cytological type. - To evaluate the safety, tolerability and feasibility of bendamustine in combination with rituximab as 1st line in patients with follicular lymphoma, 1-3A cytological type. - To evaluate the impact of the regimen modification (bendamustine dose modification and/or extension of inter-cycle interval) into duration of complete and partial responses. - To evaluate estimated treatment duration, reasons of treatment withdrawal. - To evaluate the possibility of unification and standardization of therapy protocol BR (rituximab 375 mg/m2 on day 1 and bendamustine 90 mg/m2 on days 1-2). - To evaluate factors affecting overall and progression-free survival.

Phase:

Phase 3

Details

Lead Sponsor:

National Research Center for Hematology, Russia

Treatments:

Bendamustine Hydrochloride
Rituximab